

# **The Microbiota and Individual Community Members in Colorectal Cancer: Is There a Common Theme?**

Marc A Sze<sup>1</sup> and Patrick D Schloss<sup>1†</sup>

† To whom correspondence should be addressed: [pschloss@umich.edu](mailto:pschloss@umich.edu)

<sup>1</sup> Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

Co-author e-mails:

- [marcsze@med.umich.edu](mailto:marcsze@med.umich.edu)

1 **Abstract**

2 **Background.**

3 **Results.**

4 **Conclusions.**

5 **Keywords**

6 microbiota; colorectal cancer; polyps; adenoma; meta-analysis.

## 7 Background

## Results

### ***Fecal Diversity is Lower in Those with Carcinoma and Increases Relative Risk:***

Using power transformed and Z-score normalized alpha diversity metrics both evenness and the Shannon diversity metrics in feces are lower in those with carcinoma than in controls but not for tissue samples [Figure 1]. Using linear mixed-effects to control for study and variable region there was a significant decrease from control to adenoma to carcinoma for both evenness (P-value = 0.025) and Shannon diversity (P-value = 0.043). This effect was not observed in tissue when additionally controlling for whether the sample came from the same individual (P-value > 0.05). For fecal samples a decrease in Shannon diversity and evenness resulted in a significantly increased relative risk for carcinoma (P-value = 0.01 and P-value = 0.0011, respectively) [Figure 2]. Although these values were significant the effect size was relatively small for both metrics (Shannon RR = 1.31 and evenness RR = 1.34) [Figure 2]. There was no increased relative risk for these metrics for adenoma or for tissue in general [Figure S1-3].

Using the Bray-Curtis distance metric, the fecal microbiota did not have a different community diversity between adenoma and control but did for carcinoma across studies [Table S1 & S2]. The majority of unmatched tissue samples had a significant difference for both adenoma and carcinoma versus controls [Table S3 & S4]. All matched tissue samples across studies had no difference between any of the compared groups [Table S3 & S4].

### ***Genera Previously Associated with Carcinoma Increases Relative Risk More than***

***Alpha Diversity:*** Both fecal and tissue samples had a significantly increased RR for carcinoma but not for adenoma [Figure 3] which was greater than either evenness or Shannon diversity [Figure 2 & 3]. The relative risk did not increase when considering the total abundance or increasing number of carcinoma associated genera [Figure 3]. The RR effect size was greater for stool (RR range = 1.78 - 2.64) than for tissue (RR range = 1.33 -

1.53). This decrease may be explained by the fact that tissue samples include matched samples.

***Using the Whole Community Increases Model AUC over CRC Associated Genera:***

For both fecal and tissue samples (matched and unmatched) there was a decrease in AUC when only OTUs from the CRC associated genera are used [Figure 4 & 5]. This decrease is observed in both adenoma and carcinoma groups [Figure 4 & 5]. The genus models generally had similar trends as observed for the OTU based models with the full genera models performing better than the CRC associated genera models [Figure S4-S5]. Both genus models perform similarly in their ability to be able to predict lesion (adenoma or carcinoma) with carcinoma having a higher AUC than adenoma [Figure S6-S8]. Matched tissue samples for those with carcinoma had an AUC that was more similar to the adenoma models [Figure S6A, S7B, & S8] than carcinoma models [Figure S6B & S7A].

***Majority of Studies are Underpowered for Detecting Small Effect Size Differences:***

When assessing the power of each study at different effect sizes the majority of studies for both adenoma and carcinoma have an 80% power to detect a 30% difference [Figure 6A & B]. No single study that was analyzed had the standard 80% power to detect a difference that was equal to or below 10% [Figure 6A & B]. In order to achieve adequate power for small effect sizes it would be necessary to recruit over 1000 individuals for each arm of the study [Figure 6C].

## Discussion

Our study identifies clear diversity changes both at the community level and within individual genera that are present in individuals with carcinoma versus those without the disease. Although there was a step wise decrease in diversity from control to adenoma to carcinoma; this did not translate into large effect sizes for the relative risk of either of these two conditions. These clear changes were not easily recapitulated in those with adenoma. Even though CRC associated genera increase the relative risk of carcinoma they do not increase the relative risk of adenoma. This information suggests that these specific genera may not be the primary members of the microbial community that contributes to the formation of an adenoma but is for a carcinoma. Additionally, our data shows that by using the whole community our models perform better then when they only use the CRC associated genera. CRC associated genera are clearly important to carcinoma but the context or community in which these microbes are a part of can drastically increase the ability of models to make predictions. This data supports the concept that small localized changes within the community may be occurring that are important in the disease progression of colorectal cancer and that they may not directly involve CRC associated genera.

The driver-passenger model of the microbial role in CRC, as summarized by Flynn [1], can be supported with this data for carcinoma but not necessarily for adenoma. The drastically increased relative risk of disease when considering the CRC associated genera is highly supportive of this type of process. In a driver-passenger scenario it is possible that simply having the driver present or only identifying the passenger is a good enough proxy that the event is occurring. This would account for the observation that there is no synergistic increase in relative risk when accounting for either the total number or increasing abundance of these genera. The initial establishment of the driver within the system is also dependent on the community that is present and this could explain why adding the community context

to our models increases the prediction. Although the driver-passenger model fits well with the transtion of adenoma to carcinoma for our carcinoma observations it does not fit well with our observed data on control to adenoma.

- Building on this idea moving forward how CRC associated genera interact with the overall community rather than in isolation will be important since they do not increase the RR of polyps
- suggesting localized changes to community may be more important
- In closing to get at these more difficult questions the Power calculations and effect size in future studies need to be accounted for especially for adenoma where the predicted effect sizes are going to be small

## Conclusion

-aggregate studies done with feces and stool to investigate the role of the microbiota in adenoma and carcinoma.

- Significantly adds to the existing research using this approach by expanding both the total individuals included and the scope.
- leads to clear identifications of the challenges that lie ahead with respect to adenoma

## Methods

**Obtaining Data Sets:** Studies used for this meta-analysis were identified through the review articles written by Keku, et al. and Vogtmann, et al. [2,3]. All studies were included that used tissue or feces as their sample source for 16S rRNA gene sequencing analysis. Studies using either 454 or Illumina sequencing technology were included. Only data sets that had the raw sequences available for analysis were included. Some studies did not have publically available raw sequences or did not have meta data in which the authors were able to share. After this filtering step the following studies remained: Ahn [4], Baxter [5], Brim [6], Burns [7], Chen [8], Dejea [9], Flemer [10], Geng [11], Hale [12], Kostic [13], Lu [14], Sanapareddy [15], Wang [16], Weir [17], and Zeller [18]. The Zackular [19] study was not included because the 90 individuals analyzed within the study are contained within the larger Baxter study. The Kostic study was not used since after sequence processing all the case samples did not have more than 100 sequences remaining. This left a total of 13 studies in which complete analysis could be completed.

**Data Set Breakdown:** In total there were 7 studies with only fecal samples (Ahn, Baxter, Brim, Hale, Wang, Weir, and Zeller), 5 studies with only tissue samples (Burns, Dejea, Geng, Lu, Sanapareddy), and 2 studies with both fecal and tissue samples (Chen and Flemer). The total number of individuals initially run through the sequence processing for the fecal samples was 1899 and for the tissue samples was 462.

**Sequence Processing:** For the majority of studies raw sequences were downloaded from the SRA (<ftp://ftp-trace.ncbi.nih.gov/sra/sra-instant/reads/ByStudy/sra/SRP/>) and metadata was obtained from the following website: <http://www.ncbi.nlm.nih.gov/Traces/study/> by searching the respective accession number of the study. Of the studies that did not have sequences and meta data on the SRA one study had the data stored on DBGap [4] and four studies the data was obtained directly from the authors [10,12,15,17]. Each



study was processed using the mothur (v1.39.3) software program [20]. Where possible quality filtering utilized the default methods used in mothur for either 454 or Illumina based sequencing. If it was not possible to use these defaults the author stated quality cut-offs were used instead. Chimeras were identified and removed using the VSEARCH [??] program and *de novo* OTU clustering at 97% similarity using the OptiClust algorithm [21] was utilized.

**Statistical Analysis:** All statistical analysis after sequence processing utilized the R software package (v3.4.2). For the alpha diversity analysis values were power transformed using the rcompanion (v1.10.1) package and then Z-score normalized using the car (v2.1.5) package. Testing for alpha diversity differences utilized linear mixed-effect models created using the lme4 (v1.1.14) package to correct for both study and variable region effect in the diversity measures when analyzing colorectal cancer groups. Relative Risk was analyzed using both the epiR (v0.9.87) and metafor (v2.0.0) packages. Relative risk significance testing utilized the chi-squared test. Beta-diversity differences utilized a Bray-Curtis distance matrix and PERMANOVA executed with the vegan (v2.4.4) package. Random Forest models were built using both the caret (v6.0.77) and randomForest (v4.6.12) packages. Random Forest testing of the obtained AUC versus a random model AUC utilized T-tests. Power analysis and estimations were made using the pwr (v1.2.1) and statmod (v1.4.30) packages. All figures were created using both ggplot2 (v2.2.1) and gridExtra (v2.3) packages.

**Study Analysis Overview:** Alpha diversity was first assessed for differences between controls and adenoma versus cancer and controls versus adenoma. We analyzed the data using linear mixed-effect models, and relative risk. Beta-diversity was then assessed for each individual study. Next, four specific CRC-associated genera (*Fusobacterium*, *Parvimonas*, *Peptostreptococcus*, and *Porphyromonas*) were assessed for differences in relative risk. We then built Random Forest models based on all genera or the select

CRC-associated genera. The models were trained on one study then tested on the remaining studies for every study. The data was split between feces and tissue samples. Within the tissue groups the data was further divided between matched and unmatched tissue samples. Both prediction for adenoma and carcinoma were tested. This same approach was then applied at the OTU level with the exception that instead of testing on the other studies a 10-fold cross validation was utilized and 100 different models were created based on random 80/20 splitting of the data to generate a range of expected AUCs. For OTU based models the CRC Associated Genera included all OTUs that had a taxonomic classification to *Fusobacterium*, *Parvimonas*, *Peptostreptococcus*, or *Porphyromonas*. The power of each study was assessed for and effect size ranging from 1% to 30%. An estimated sample n for these effect sizes was also generated based on 80% power.

**Reproducible Methods:** The code and analysis can be found here [https://github.com/SchlossLab/Size\\_CRCMetaAnalysis\\_Microbiome\\_2017](https://github.com/SchlossLab/Size_CRCMetaAnalysis_Microbiome_2017). Unless mentioned otherwise the accession number for the raw sequences for the studies used in this analysis can be found directly in the respective batch file, on the GitHub repository or in the original manuscript.

## **Declarations**

### **Ethics approval and consent to participate**

Ethics approval and informed consent for each of the studies used is mentioned in the respective manuscript used in this meta-analysis.

### **Consent for publication**

Not applicable.

### **Availability of data and material**

A detailed and reproducible description of how the data were processed and analyzed for each study can be found at [https://github.com/SchlossLab/Size\\_CRCMetaAnalysis\\_Microbiome\\_2017](https://github.com/SchlossLab/Size_CRCMetaAnalysis_Microbiome_2017). Raw sequences can be downloaded from the SRA in most cases and can be found in the respective studies batch file in the GitHub repo or within the original publication. When sequences were not publicly available contacting the corresponding author for raw sequences needs to be undertaken.

### **Competing Interests**

All authors declare that they do not have any relevant competing interests to report.

## **Funding**

MAS is supported by a CIHR fellowship and a University of Michigan PTSP fellowship grant.

## **Authors' contributions**

All authors helped to design and conceptualize the study. MAS identified and analyzed the data. MAS and PDS interpreted the data. MAS wrote the first draft of the manuscript and both he and PDS reviewed and revised updated versions. All authors approved the final manuscript.

## **Acknowledgements**

The authors would like to thank all the study participants who were apart of each of the individual studies uiltized. We would also like to thank each of the study authors for making their data available for use. Finally we would like to thank the members of the Schloss lab for valuable feed back and proof reading during the formulation of this manuscript.

## References

1. Flynn KJ, Baxter NT, Schloss PD. Metabolic and Community Synergy of Oral Bacteria in Colorectal Cancer. *mSphere*. 2016;1.
2. Keku TO, Dulal S, Deveau A, Jovov B, Han X. The gastrointestinal microbiota and colorectal cancer. *American Journal of Physiology - Gastrointestinal and Liver Physiology* [Internet]. 2015 [cited 2017 Oct 30];308:G351–63. Available from: <http://ajpgi.physiology.org/lookup/doi/10.1152/ajpgi.00360.2012>
3. Vogtmann E, Goedert JJ. Epidemiologic studies of the human microbiome and cancer. *British Journal of Cancer* [Internet]. 2016 [cited 2017 Oct 30];114:237–42. Available from: <http://www.nature.com/doifinder/10.1038/bjc.2015.465>
4. Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. *Journal of the National Cancer Institute*. 2013;105:1907–11.
5. Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine*. 2016;8:37.
6. Brim H, Yooseph S, Zoetendal EG, Lee E, Torralbo M, Laiyemo AO, et al. Microbiome analysis of stool samples from African Americans with colon polyps. *PloS One*. 2013;8:e81352.
7. Burns MB, Lynch J, Starr TK, Knights D, Blekhman R. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. *Genome Medicine*. 2015;7:55.
8. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated

209 microbiota in patients with colorectal cancer. PloS One. 2012;7:e39743.

210 9. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al.  
211 Microbiota organization is a distinct feature of proximal colorectal cancers. Proceedings of  
212 the National Academy of Sciences of the United States of America. 2014;111:18321–6.

213 10. Flemer B, Lynch DB, Brown JMR, Jeffery IB, Ryan FJ, Claesson MJ, et al.  
214 Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut.  
215 2017;66:633–43.

216 11. Geng J, Fan H, Tang X, Zhai H, Zhang Z. Diversified pattern of the human colorectal  
217 cancer microbiome. Gut Pathogens. 2013;5:2.

218 12. Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, et al. Shifts in the Fecal  
219 Microbiota Associated with Adenomatous Polyps. Cancer Epidemiology, Biomarkers &  
220 Prevention: A Publication of the American Association for Cancer Research, Cosponsored  
221 by the American Society of Preventive Oncology. 2017;26:85–94.

222 13. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic  
223 analysis identifies association of Fusobacterium with colorectal carcinoma. Genome  
224 Research. 2012;22:292–8.

225 14. Lu Y, Chen J, Zheng J, Hu G, Wang J, Huang C, et al. Mucosal adherent bacterial  
226 dysbiosis in patients with colorectal adenomas. Scientific Reports. 2016;6:26337.

227 15. Sanapareddy N, Legge RM, Jovov B, McCoy A, Burcal L, Araujo-Perez F, et al.  
228 Increased rectal microbial richness is associated with the presence of colorectal adenomas  
229 in humans. The ISME journal. 2012;6:1858–68.

230 16. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut  
231 microbiota between colorectal cancer patients and healthy volunteers. The ISME journal.

232 2012;6:320–9.

233 17. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome  
234 and metabolome differences between colorectal cancer patients and healthy adults. *PloS*  
235 *One*. 2013;8:e70803.

236 18. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of  
237 fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*.  
238 2014;10:766.

239 19. Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as  
240 a screening tool for colorectal cancer. *Cancer Prevention Research (Philadelphia, Pa.)*.  
241 2014;7:1112–21.

242 20. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al.  
243 Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software  
244 for Describing and Comparing Microbial Communities. *Appl.Environ.Microbiol.* [Internet].  
245 2009 [cited 12AD Jan 1];75:7537–41. Available from: [http://aem.asm.org/cgi/content/](http://aem.asm.org/cgi/content/abstract/75/23/7537)  
246 [abstract/75/23/7537](http://aem.asm.org/cgi/content/abstract/75/23/7537)

247 21. Westcott SL, Schloss PD. OptiClust, an Improved Method for Assigning  
248 Amplicon-Based Sequence Data to Operational Taxonomic Units. *mSphere*. 2017;2.





250 **Figure 1:**

251 **Figure 2:**

252 **Figure 3:**

253 **Figure 4:**

254 **Figure 5:**

255 **Figure 6:**

256 **Figure S1:**

257 **Figure S2:**

258 **Figure S3:**

259 **Figure S4:**

260 **Figure S5:**

261 **Figure S6:**

262 **Figure S7:**

263 **Figure S8:**